Predict your next investment

CONSUMER PRODUCTS & SERVICES | Health & Wellness (non-internet/mobile)

See what CB Insights has to offer

Founded Year



Acquired | Acquired

About ScaleDown

ScaleDown is a new approach to weight loss using the science of self-regulation and daily weighing to help lose weight quickly and easily.

ScaleDown Headquarter Location

222 W Merchandise Mart Plaza Suite 1230

Chicago, Illinois, 60654,

United States

Latest ScaleDown News

Weight Loss Intervention Fails in Endometrial Cancer Survivors

Apr 8, 2020

NewsDio By Nearly half of the obese endometrial cancer survivors in a recent study gained weight over 12 months of follow-up, regardless of whether or not they participated in a behavioral intervention to lose weight. Of the 358 endometrial cancer survivors with a body mass index of at least 30 kg / m2 who were contacted to participate in the ScaleDown randomized trial, 80 participated and 278 declined. The results of that study, which compared a "high-tech" weight loss intervention with "improved usual care," were reported last year (Gynecol Oncol. 2019 Jun; 154 (1): 20). The goal of the ScaleDown trial was to identify a "better stimulus mechanism for weight loss for our patients," said Abigail Zamorano, MD, of the University of Washington, St. Louis. "Unfortunately, we found that there was no difference in those two groups. It was quite disappointing." Dr. Zamorano and colleagues hypothesized that although the women who participated in the study failed to lose weight, they may have gained less than the women who did not participate. Therefore, the researchers conducted a retrospective study comparing the two groups. The researchers reported the results of this study in a summary that was scheduled for presentation at the Annual Meeting of the Society of Gynecological Oncology for Women's Cancer. The meeting was canceled due to the COVID-19 pandemic. Retrospective results At both 6-month and 12-month follow-up, there were no significant differences between ScaleDown participants and non-participants with respect to change in BMI from baseline (P = .77 and P = .76, respectively). "In essence, unfortunately we also found no difference in BMI change in these two groups," said Dr. Zamorano. At 12 months, the rates of weight loss and gain were similar for ScaleDown participants and nonparticipants: 49.2% and 47%, respectively, gained weight. 13.9% and 23.2%, respectively, lost 0% to 2.5% of weight. 10.8% and 7.1%, respectively, lost 2.5% to 4% of weight. 3.1% and 4.8%, respectively, lost 4% to 5% of weight. 23.1% and 17.9%, respectively, lost 5% or more of weight. Compared to participants, nonparticipants were significantly more likely to be white and older (63.4 years vs. 59.3 years), with more medications (median 7 vs. 4), they had a lower mean BMI (39 , 1 kg / m2 vs. 41.7 kg / m2), were more likely to have recurrent cancer (15.2% vs. 5.1%), and were less likely to have had genetic counseling (10.8% vs. to 20%). There were no differences between the groups in terms of cancer histology, stage or reception of initial chemotherapy or radiotherapy. How can oncologists help patients lose weight? "Overall, I would say that the findings for the primary goal were not particularly encouraging," said Dr. Zamorano. However, he said an important message emerged from some of the survey results: Patients were very frustrated with their weight loss journey. Many said that despite having a desire to lose weight, they did not know how and nothing seemed to work. This suggests that, with the right strategies, oncologists are in a position to help, Dr. Zamorano said. "As their oncologists who see them regularly for years and years, even after completing their primary cancer therapy … we have a unique relationship with them," he explained. "We have this unique role that we can play, so we need to think a little bit outside the box about how we can help our patients lose weight." This is important to try because thousands of women are diagnosed with endometrial cancer in the United States each year, and while many will be "successfully treated from a cancer perspective because they are diagnosed at an early stage," they may also have significant comorbidities, more frequently. obesity, said Dr. Zamorano. "And along with that … diabetes and cardiovascular disease," he added. "That means they have a very high risk of long-term complications from obesity, and while we are addressing their cancer, we were not addressing those other complications." A possible solution is bariatric surgery. Weight loss surgery has been shown to improve health care outcomes and reduce mortality rates and costs, however 89% of ScaleDown participants said they had never considered it, and 67% said they would reject a referral. This suggests that, despite the available evidence of benefit in candidate patients, there is a knowledge gap in awareness of the effectiveness and safety of bariatric surgery in this population, said Dr. Zamorano. "Given the obesity-related health problems this population has, we should really address weight as part of the essential cancer management strategy rather than an afterthought," he said, adding that it should be incorporated at the outset and potentially include a referral to surgical weight loss. Dr. Zamorano reported having no disclosures. The research was funded by the University of Washington. SOURCE: Zamorano A et al. SGO 2020, Summary 20. This story originally appeared on . (tagsToTranslate) weight loss (t) weight control (t) cancer (t) malignancy (t) carcinoma (t) weight gain (t) cancer survivor (t) bariatric surgery (t) obesity surgery (t ) weight loss surgery (t) surgery (weight loss) (t) diabetes mellitus (t) obesity (t) obesity (t) chemotherapy (t) radiation oncology (t) body mass index (BMI); bmi (body mass index) (t) Washington (t) Coronavirus (t) 2019 New coronavirus (t) 2019-nCoV (t) Wuhan coronavirus (t) Human coronavirus HKU1 (t) Human crown

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.